Therapy in Amyotrophic Lateral Sclerosis (TAME)
Public ClinicalTrials.gov record NCT02118727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD)
Study identification
- NCT ID
- NCT02118727
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 89 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2018 (Actual)
- Primary completion
- Jul 22, 2021 (Actual)
- Completion
- Jul 22, 2021 (Actual)
- Last update posted
- Nov 29, 2022
2018 – 2021
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Neurological Associates | Phoenix | Arizona | 85018 | — |
| UC Irvine | Irvine | California | 92868 | — |
| University of Florida | Jacksonville | Florida | 32209 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| University of Kansas School of Medicine - Wichita | Wichita | Kansas | 67214 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| University of Missouri | Columbia | Missouri | 65201 | — |
| CoxHealth | Springfield | Missouri | 65802 | — |
| Providence Health Sciences | Portland | Oregon | 97225 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Austin Neuromuscular Center | Austin | Texas | 78759 | — |
| Nerve & Muscle Center of Texas | Houston | Texas | 77030 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02118727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02118727 live on ClinicalTrials.gov.